Related Experiment Video
Updated: Apr 23, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
New oral anticoagulants in thrombotic antiphospholipid syndrome
C B Chighizola1, M Moia2, P L Meroni3
1Experimental Laboratory of Immunological and Rheumatologic Researches, IRCCS Istituto Auxologico Italiano, Milan, Italy Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Abstract:
A main goal in clinical management of patients with antiphospholipid syndrome (APS) is to prevent thrombotic recurrences and/or miscarriages. For many decades, the only available oral anticoagulant drugs have been vitamin K antagonists (VKA), which are still the cornerstone of long-term treatment of thromboembolism. However, the limits of VKA treatment are well known: narrow therapeutic window and high patient-to-patient variability of response. Moreover, in some patients with APS a higher international normalized ratio (INR) therapeutic target was suggested, and INR inaccuracy due to antiphospholipid antibodies was reported. Therefore, VKA management in APS patients is frequently cumbersome, requires close INR monitoring and may affect patient's quality of life. A new class of oral anticoagulant agents has been developed, the Direct Oral Anticoagulants (DOA), which directly inhibit a single enzyme of the coagulation cascade. Compared with VKA, they have more stable pharmacokinetic and pharmacodynamic profiles, little interaction with food or drugs with a predictable anticoagulation effect, they can thus be prescribed in a fixed dose, without requiring frequent laboratory monitoring. The efficacy and safety of DOA has been shown in large phase III clinical trials. Unfortunately, translating these good results to APS patients is not straightforward: currently, at least three randomized controlled clinical trials are ongoing.
Insights
Direct Oral Anticoagulants (DOA) offer a promising alternative to Vitamin K Antagonists (VKA) for antiphospholipid syndrome (APS) patients. Ongoing trials are evaluating DOA efficacy and safety in APS, aiming to improve thrombotic event prevention.
Area of Science:
- Hematology
- Clinical Pharmacology
- Immunology
Background:
- Antiphospholipid syndrome (APS) management primarily focuses on preventing thrombotic events and miscarriages.
- Vitamin K Antagonists (VKA) are the traditional oral anticoagulants but have limitations including narrow therapeutic windows and variable responses.
- VKA management in APS can be challenging due to INR monitoring difficulties and potential inaccuracies caused by antiphospholipid antibodies.
Purpose of the Study:
- To evaluate the potential of Direct Oral Anticoagulants (DOA) as an alternative to VKA in APS patients.
- To assess the efficacy and safety of DOA in preventing thrombotic recurrences and miscarriages in APS.
- To address the limitations associated with VKA therapy in APS management.
Main Methods:
- Review of current clinical practices and limitations of VKA in APS.
- Introduction of Direct Oral Anticoagulants (DOA) as a novel class of anticoagulants.
- Mention of ongoing randomized controlled clinical trials investigating DOA in APS patients.
Main Results:
- DOA offer stable pharmacokinetic and pharmacodynamic profiles with predictable anticoagulation.
- DOA can be prescribed in fixed doses without frequent laboratory monitoring, unlike VKA.
- Translating DOA efficacy and safety data from general populations to APS patients requires further investigation.
Conclusions:
- DOA represent a potential advancement in anticoagulation therapy for APS.
- Further research through ongoing clinical trials is crucial to establish the role of DOA in APS management.
- DOA may offer improved quality of life for APS patients by simplifying treatment regimens.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:30Venous Thrombosis I: Introduction